Art Levinson, Sergey Brin And Anne Wojcicki, Mark Zuckerberg And Priscilla Chan, And Yuri Milner Announce The Breakthrough Prize In Life Sciences
Distinguished Professor of Pathology and Senior Deputy Director for Basic Sciences at Moores Cancer Center at the University of California, San Diego.
For discoveries in the mechanisms of angiogenesis that led to therapies for cancer and eye diseases.
Eric S. LanderPresident and Founding Director of the Eli and Edythe L. Broad Institute of Harvard and MIT. Professor of Biology at MIT. Professor of Systems Biology at Harvard Medical School. For the discovery of general principles for identifying human disease genes, and enabling their application to medicine through the creation and analysis of genetic, physical and sequence maps of the human genome Charles L. Sawyers Chair, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center. Howard Hughes Medical Institute Investigator. For cancer genes and targeted therapy. Bert Vogelstein Director of the Ludwig Center and Clayton Professor of Oncology and Pathology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Howard Hughes Medical Institute Investigator. For cancer genomics and tumor suppressor genes. Robert A. Weinberg Daniel K. Ludwig Professor for Cancer Research at MIT and Director of the MIT/Ludwig Center for Molecular Oncology. Member, Whitehead Institute for Biomedical Research. For characterization of human cancer genes. Shinya Yamanaka Director of Center for iPS Cell Research and Application, Kyoto University Senior Investigator, Gladstone Institutes, San Francisco For induced pluripotent stem cells. About the participants: Art Levinson Arthur D. Levinson is chairman of Genentech, Inc. and a member of the Roche Board of Directors. He has been chairman of Genentech since 1999, and he served as chief executive officer of Genentech from 1995 to 2009. Levinson joined Genentech in 1980 as a research scientist and became vice president, Research Technology in 1989; vice president, Research in 1990; senior vice president, Research in 1992; and senior vice president, Research and Development in 1993. Art was appointed Chairman of the Board of Apple in November 2011. He had served as a co-lead director of Apple's board since 2005 and a director since 2000. He is Chairman of the Board of Amyris and a director of NGM Biopharmaceuticals, Inc. and the Broad Institute of MIT and Harvard. He was a director of Google, Inc. from 2004 to 2009. He currently serves on the Board of Scientific Consultants of the Memorial Sloan-Kettering Cancer Center, the Industrial Advisory Board of the California Institute for Quantitative Biomedical Research, the Advisory Council for the Princeton University Department of Molecular Biology and the Advisory Council for the Lewis-Sigler Institute for Integrative Genomics. Art has authored or co-authored more than 80 scientific articles and has been a named inventor on 11 United States patents. Art received his Bachelor of Science degree from the University of Washington and earned a doctorate in Biochemical Sciences from Princeton University. Mark Zuckerberg Mark Zuckerberg is the founder chairman and CEO of Facebook, which he founded in 2004 in his college dorm room. Mark is responsible for setting the overall direction and product strategy for Facebook. He leads the design of Facebook's service and the development of its core technology and infrastructure.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV